Immunofixation, Isatuximab-Specific, Serum
Also known as: Electrophoresis, Serum, IFE, HYDRASHIFT 2/4 isatuximab, IEP, Serum, IFE, Serum, Immunoelectrophoresis, Serum
Use
Detect and identify monoclonal immunoglobulin gammopathies in the presence of therapeutic monoclonal antibody (mAbs) drug treatment with isatuximab (SARCLISA®), a human IgG1 kappa mAb, which migrates in the electrophoretic gamma globulin zone of the electrophoresis gel. In this laboratory procedure, the isatuximab in vitro interference is removed using an anti-isatuximab antibody reagent. This procedure will characterize the specific light and heavy chain components of a monoclonal protein without isatuximab interference.
Special Instructions
Patient's age and clinical diagnosis should be stated on the test request form. Overnight fasting is preferred but not required.
Limitations
Interference from therapeutic monoclonal antibodies such as isatuximab can affect the electrophoresis results, but the use of the HYDRASHIFT 2/4 isatuximab reagent helps mitigate this by facilitating the migration of isatuximab/anti-Isatuximab complexes. A complete response to therapy or strict complete response can be suggested by a negative immunofixation result along with clinical assessment.
Methodology
Immunoassay
Biomarkers
LOINC Codes
- 14895-7
- 2465-3
- 2458-8
- 2472-9
Result Turnaround Time
4-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
Red-top tube or gel-barrier tube
Collection Instructions
Separate serum from red cells.
Patient Preparation
Overnight fasting is preferred but not required.
Storage Instructions
Room temperature
Causes for Rejection
Plasma sample
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |